Roche says its investigational breast cancer pill could outsell Herceptin
Roche still has high sales hopes for its breast cancer pill giredestrant despite the drug’s failure in a first-line trial earlier this year. CEO Thomas Schinecker said Thursday that the drug could ...
Thomas Schinecker, Roche CEO (Betty Laura Zapata/Bloomberg via Getty Images) April 23, 2026 06:47 AM EDTUpdated 10:43 AM Pharma Updated: Roche says its investigational breast cancer pill could outsell Herceptin Elizabeth Cairns Senior biopharma journalist Roche still has high sales hopes for its breast cancer pill giredestrant despite the drug’s failure in a first-line trial earlier this … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that